Article ; Online: Preclinical safety evaluation of calcineurin inhibitors delivered through an intraductal route to prevent post-ERCP pancreatitis demonstrates endocrine and systemic safety.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.
2023 Volume 23, Issue 4, Page(s) 333–340
Abstract: Objective: There is an urgent need for safe and targeted interventions to mitigate post-ERCP pancreatitis (PEP). Calcineurin inhibitors (CnIs) offer therapeutic promise as calcineurin signaling within acinar cells is a key initiating event in PEP. In ... ...
| Abstract | Objective: There is an urgent need for safe and targeted interventions to mitigate post-ERCP pancreatitis (PEP). Calcineurin inhibitors (CnIs) offer therapeutic promise as calcineurin signaling within acinar cells is a key initiating event in PEP. In previous proof-of-concept studies using experimental models, we showed that concurrent intra-pancreatic ductal administration of the CnIs, tacrolimus (Tac) or cyclosporine A (CsA) with the ERCP radiocontrast agent (RC) prevented PEP. To translate this finding clinically, we investigated potential toxic effects of intraductal delivery of a single-dose RC-CnI formulation on endocrine pancreas function and systemic toxicities in a preclinical PEP model. Methods: C57BL/6J mice underwent ductal cannulation and received a single, intra-pancreatic ductal infusion of RC or RC with Tac or CsA (treatment groups) or underwent ductal cannulation without infusion ('sham' group). To assess endocrine function, intraperitoneal glucose tolerance test (IPGTT) was performed at two days before infusion and on day 2 and 14 post-surgery. To evaluate off-target tissue toxicities, renal and hepatic function-related parameters including blood urea nitrogen, plasma creatinine, potassium, aspartate aminotransferase, alanine aminotransferase, and total bilirubin were measured at the same time-points as IPGTT. Histological and biochemical indicators of pancreas injury and inflammation were also evaluated. Results: No abnormalities in glucose metabolism, hepatic or renal function were observed on day 2 or 14 in mice administered with intraductal RC or RC with Tac or CsA. Conclusion: Intraductal delivery of RC-CnI formulation was safe and well-tolerated with no significant acute or subacute endocrine or systemic toxicities, underscoring its clinical utility to prevent PEP. |
|---|---|
| MeSH term(s) | Mice ; Animals ; Calcineurin Inhibitors/therapeutic use ; Calcineurin Inhibitors/pharmacology ; Cholangiopancreatography, Endoscopic Retrograde/adverse effects ; Mice, Inbred C57BL ; Tacrolimus/therapeutic use ; Tacrolimus/pharmacology ; Cyclosporine/therapeutic use ; Pancreatitis/etiology ; Pancreatitis/prevention & control ; Pancreatitis/pathology ; Contrast Media |
| Chemical Substances | Calcineurin Inhibitors ; Tacrolimus (WM0HAQ4WNM) ; Cyclosporine (83HN0GTJ6D) ; Contrast Media |
| Language | English |
| Publishing date | 2023-03-30 |
| Publishing country | Switzerland |
| Document type | Journal Article |
| ZDB-ID | 2056680-3 |
| ISSN | 1424-3911 ; 1424-3903 |
| ISSN (online) | 1424-3911 |
| ISSN | 1424-3903 |
| DOI | 10.1016/j.pan.2023.03.009 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 5553: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.